Gallus Biopharmaceuticals - Ownership and Business Overview

Life ScienceCompany

Gallus Biopharmaceuticals Ownership

Who owns Gallus Biopharmaceuticals?

Gallus Biopharmaceuticals is owned by DPx Holdings BV. It was acquired on August 27, 2014.

Was Gallus Biopharmaceuticals formerly PE-backed?

Yes. Gallus Biopharmaceuticals was formerly owned by 1 private investor.

Gallus Biopharmaceuticals Business Overview

Where is Gallus Biopharmaceuticals headquartered?

Gallus Biopharmaceuticals is headquartered in St. Louis, Montana.

What sector is Gallus Biopharmaceuticals in?

Gallus Biopharmaceuticals is a life science company.

Life Science M&A Summary in 2014

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2014. The largest life science acquisition in 2014 was InterMune - which was acquired by Roche Holding AG for $8.3B.

Join Mergr to view all 237 acquisitions of life science companies in 2014, including 22 acquisitions by private equity firms, and 215 by strategics.

Gallus Biopharmaceuticals LLC

4766 LaGuardia Drive,
St. Louis, Montana 63134-3117
United States,
(314) 426-5000
www.gallusbiopharma.com

Gallus BioPharmaceuticals is a contract manufacturing company offering exceptional contract services to its clients. Gallus’ world-class facility in St. Louis is distinguished by nearly three decades of biologics development and over a decade of commercial cGMP manufacturing, including the ongoing manufacture of Remicade® and Stelara® for Janssen Pharmaceuticals.


 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.